trial

Target Engagement and Response to Oxytocin

NCTId NCT03245437
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 120 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2024-07-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-01-04
Primary completion
2024-07-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Oxytocin nasal spraySocial Cognition Skills TrainingHealth Management

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Stephen R. Marder, MDPrincipal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE4
Primary Completion Date
2024-07-31
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin nasal spray
drug
Social Cognition Skills Training
drug
Health Management
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Stephen R. Marder, MD
person